Skip to main content
. 2019 Oct 17;7:e7815. doi: 10.7717/peerj.7815

Figure 1. Illustration of experimental schedule and establishment of db/db diabetic mice model.

Figure 1

(A) All mice at 8-week-old began blood glucose monitoring for 3 weeks to determine diabetes. Db/db mice were treated with rosiglitazone (20 mg/kg/d × 28d, i.g.) or vehicle at 11-week-old for consecutive 4 weeks, and C57BL/6 mice also received RSG or vehicle. At 15-week-old, mice were further divided into 2 cohorts: wound closure creation and BM-EPC harvest. (B) Significant elevation of the blood glucose was shown in db/db mice compared with control group. RSG treatment greatly decreased the blood glucose (C), increased the serum insulin levels (D) and lighten the body weight in db/db mice (E). Values are mean ± SEM, (n = 6 per group). ∗P < 0.05 vs. Control; #P < 0.05 vs. db/db. RSG, rosiglitazone.